Actual Medicinal Product (AMP) Mylatrip 2.5mg tablets (Viatris UK Healthcare Ltd)
Stability Information
(Some stability information inherited from generic)
- Stability
-
Lack of data and/or stability concerns exist. MCA use may be acceptable but is likely to be off-label and require mitigation measures. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.
- Notes
-
Protect from moisture.
- Provenance
-
This compatibility recommendation is derived from Migard 2.5mg tablets (A. Menarini Farmaceutica Internazionale SRL).
- Generic
- Frovatriptan
- Formulation
- Frovatriptan 2.5mg tablets
-
Frovatriptan
-
Frovatriptan 2.5mg tablets
-
Mylatrip 2.5mg tablets (Viatris UK Healthcare Ltd)
-
-